Icotrokinra (Icotyde): The New Psoriasis Pill Explained for Indian Patients

October 2, 2026

Icotrokinra, sold as Icotyde, is a new once-a-day tablet for moderate to severe plaque psoriasis. It blocks the same IL-23 pathway that several injectable biologics target. It was approved in the United States in March 2026 and in the European Union in September 2026. As of 1 October 2026, we could not find any approval or launch in India, so Indian patients cannot yet get it through a normal prescription.

If you are new to the idea of targeted treatments, start with our complete guide to biologics and treatment classes. This article explains what the new pill is, what the trials found, what it costs abroad and what it means for you in India today.

Key takeaways

Icotrokinra (brand name Icotyde) is the first approved pill that blocks the IL-23 receptor. Until now, IL-23 blockers were injections only.
It is approved in the US (March 2026) and EU (September 2026) for moderate to severe plaque psoriasis in adults and children aged 12 and above who weigh at least 40 kg.
In large trials, about 65–71% of people reached clear or almost clear skin at 16 weeks, compared with about 8–11% on placebo.
It is not yet approved or launched in India as far as we could find. The US price is above US$10,000 a month.
Indian patients already have oral options such as methotrexate, cyclosporine, acitretin and apremilast, prescribed and monitored by a dermatologist.
Another new pill, zasocitinib, showed strong head-to-head results in September 2026 but is still under review and not approved anywhere.

What is icotrokinra and how does it work?

Psoriasis is driven by an overactive immune signal. One important messenger in that signal is a protein called interleukin-23 (IL-23). When IL-23 attaches to its receptor on immune cells, it keeps the inflammation going, and the skin makes new cells too fast. That is what produces thick, red, scaly plaques.

Several biologic injections already block IL-23 itself. Icotrokinra works on the other side of the lock: it is a small, specially designed peptide (a short chain of amino acids) that sits on the IL-23 receptor and stops the signal from getting through. Peptides are usually broken down in the stomach, which is why this kind of medicine has been hard to make as a pill. Johnson & Johnson describes Icotyde as the first targeted oral peptide to block the IL-23 receptor [1].

Who it is approved for

In the US and EU, icotrokinra is approved for moderate to severe plaque psoriasis in adults and adolescents aged 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy (medicines that work through the whole body) or phototherapy [1][2][3]. It is not meant for mild psoriasis that can be managed with creams and moisturisers.

How it is taken

One 200 mg tablet once a day [1].
Taken right after waking up, on an empty stomach, with plain water.
Wait at least 30 minutes before eating or drinking anything other than water [4]. For many Indian households, that means taking it before morning chai.
Swallow it whole. Do not crush, split or chew it [4].

What the trials found

Icotrokinra was tested in the ICONIC programme, a group of phase 3 trials with about 2,500 people [1][2].

Result at 16 weeks	Icotrokinra	Placebo
Clear or almost clear skin (IGA 0/1)	65–71%	8–11%
90% improvement in psoriasis score (PASI 90)	50–57%	1–4%

Figures from three trials, as summarised by the European Medicines Agency [2].

A few other findings matter for patients:

Difficult areas. One trial looked at scalp, genital, hand and foot psoriasis. At 16 weeks, about 66% of people on icotrokinra had a clear or almost clear scalp (vs about 11% on placebo), and about 77% had clear or almost clear genital skin (vs about 21%). Results on the hands and feet were smaller and not statistically significant [5].
Against another pill. In two head-to-head trials, icotrokinra did better than deucravacitinib, an existing oral psoriasis medicine [1][3].
Pooled evidence. A 2026 review combining five randomised trials found much higher odds of clear skin with icotrokinra than with placebo, and no significant difference in serious side effects or cancers over the trial periods [6].

Trials last months, not decades. Long-term safety will only become clear as more people use it over years. Everyone's skin responds differently, and no medicine works for everyone.

Side effects and safety

In the trials, side effects were reported at rates close to placebo [1][2]. The more common ones listed were:

headache
nausea
cough
fungal infections such as athlete's foot or oral thrush
tiredness

The more serious concern is infection, including tuberculosis, because the medicine damps down part of the immune system [1]. This is especially important in India, where TB is common. Doctors usually screen for TB before starting medicines like this. Live vaccines (such as MMR, chickenpox, yellow fever, rotavirus and nasal flu vaccine) should be avoided while on it; inactivated vaccines are considered fine [4].

If you are pregnant, planning a pregnancy or breastfeeding, discuss this with your doctor before starting any new systemic psoriasis medicine. The same applies to children: only a specialist should decide whether a teenager needs it.

Can you get it in India? Cost and access

Approval status

As of 1 October 2026, we found no announcement of approval by India's drug regulator, the CDSCO, and no Indian launch date from the company. New medicines usually reach India later than the US and Europe, and an Indian approval may involve local studies. Be very careful of anyone online offering "Icotyde" for sale in India. Unapproved imports can be fake, wrongly stored or simply unsafe.

What it costs abroad

In the US, the average retail price is listed at about US$10,592 a month [4]. At today's exchange rate (around ₹96 to the dollar), that is roughly ₹10 lakh a month. US patients often pay much less through insurance and company support schemes, but these do not apply in India. Even if it launches here, the Indian price may be very different, and nobody knows yet what it will be.

What Indian patients can use today

India is mostly a self-pay market for psoriasis care. An expert consensus of Indian dermatologists describes the oral medicines commonly used here: methotrexate, cyclosporine, acitretin and apremilast, alongside biologic injections [7]. The panel noted that apremilast tends to work better in mild to moderate disease and can help hard-to-treat palms and soles. Each of these needs a doctor's prescription and, for most, regular blood tests.

You can read more about two of these options in our guides to methotrexate and its real safety considerations and JAK inhibitors. For an honest picture of how long any treatment takes to show results, see how long psoriasis treatment takes to work.

Another new pill to watch: zasocitinib

On 30 September 2026, results were presented at the European dermatology congress (EADV) from a trial comparing zasocitinib, a new TYK2-blocking pill from Takeda, directly with deucravacitinib in 606 adults [8]. At 16 weeks:

36.5% on zasocitinib had completely clear skin (PASI 100), vs 13.9% on deucravacitinib.
62.5% reached PASI 90, vs 34.0%.

Zasocitinib is still an investigational medicine. The US FDA accepted its application for priority review in September 2026, and the European regulator is also reviewing it [8]. It is not approved anywhere yet, including India.

Gentle skin care still matters

Whatever treatment your doctor chooses, daily skin care helps with comfort. Lukewarm baths, a fragrance-free or gentle cleanser, and moisturising within a few minutes of bathing may help soothe dryness and itching, especially during dry North Indian winters or in air-conditioned offices. Some people also use plant-oil based products for body plaques, such as those in our psoriasis on body collection. These support your skin's comfort. They are not a replacement for prescribed treatment.

Please tell your dermatologist about every Ayurvedic or herbal medicine you take by mouth. Some herbs need care: giloy has been linked to liver injury reports in India, and many herbs have not been tested in pregnancy or in children. Never stop a prescribed treatment on your own.

When to see a doctor

See a dermatologist soon, or go to a hospital urgently, if you notice:

redness and peeling spreading over most of your body, with chills or feeling unwell (this can be erythrodermic psoriasis, an emergency)
pus-filled bumps with fever
a cough lasting more than two weeks, night sweats, weight loss or fever while on any immune-suppressing medicine (possible TB)
swollen, painful joints or morning stiffness, which may mean psoriatic arthritis
psoriasis that keeps spreading or does not respond to your current treatment after a fair trial
new symptoms after starting a medicine, such as severe stomach pain, black stools or yellowing of the eyes

Frequently asked questions

Is icotrokinra available in India?

Not as of 1 October 2026, as far as we could find. It is approved in the US and the EU. Watch for an official CDSCO approval and a company launch announcement, and avoid unofficial online sellers.

Is icotrokinra a steroid?

No. It is a targeted peptide that blocks the IL-23 receptor. It is not a corticosteroid, and it is not a JAK inhibitor.

Is the new psoriasis pill better than biologic injections?

There are no published trials comparing icotrokinra directly with IL-23 biologic injections in our sources. Its main advantage is that it is a pill. The best option for you depends on your disease, other health conditions, cost and your doctor's judgement.

Does the new pill cure psoriasis?

No current medicine cures psoriasis. Treatments like this can control it while you take them. Psoriasis may return if a medicine is stopped, so changes should always be planned with your doctor.

Can I switch from methotrexate or a biologic to this pill?

Not on your own. Switching needs a dermatologist's plan, screening tests and, in India, a legally available supply. Do not stop your current treatment while waiting for a new one.

Sources

This article is for general information and is not medical advice. Please consult a qualified dermatologist or Ayurvedic doctor for diagnosis and treatment.

Back to blog

Item added to your cart